|
|
|
|
|
3310.0: Monday, November 8, 2004: 4:30 PM-6:00 PM | |||
Oral | |||
| |||
| Learning Objectives: see individual abstracts | |||
| Marilyn C. Daley, PhD | |||
| Methadone dosage and retention: An examination of the 60mg/day threshold Thomas M. Brady, PhD, Sameena Salvucci, PhD, Lev S. Sverdlov, MD, PhD, Alisa Male, MA, Hannah Kyeyune, MS, Emmanuel Sikali, MS | |||
| Introduction to buprenorphine and office-based opioid addiction therapy under the new paradigm established by the Drug Addiction Treatment Act of 2000 Wayne Brandes, DO | |||
| Integrating methadone and buprenorphine treatment for opiate addiction into physician office settings: The San Francisco OBOT pilot program Alice A. Gleghorn, PhD, Richard Fine, MD, David Hersh, MD, Brigitte Lank, PhD, Stephanie Marsan, MD, Jim Westphal, MD | |||
Attitudes toward buprenorphine in substance abuse treatment programs ![[ Recorded presentation ]](/static/img/filetypes/16x16/wrf.gif){kind=small} Marilyn C. Daley, PhD, Dennis McCarty, PhD, Cindy Parks Thomas, PA, PhD, Traci Rieckmann, PhD | |||
| Expanding treatment options for opioid dependence: Physician acceptance of buprenorphine treatment Caroline C. McLeod, PhD, Arlene Stanton, PhD, Wendy Kissin, PhD, L. Joseph Sonnefeld, MA, James W. Luckey, PhD | |||
| See individual abstracts for presenting author's disclosure statement and author's information. | |||
| Organized by: | Alcohol, Tobacco, and Other Drugs | ||
| CE Credits: | CME, Health Education (CHES), Nursing | ||